eXoZymes Inc.
12.65+0.29 (+2.34%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · EXOZ · USD
Key Stats
Market Cap
106.07MP/E (TTM)
-Basic EPS (TTM)
-0.92Dividend Yield
0%Recent Filings
8-K
Updated investor presentation released
eXoZymes Inc. released an updated investor presentation on September 30, 2025, under Item 8.01, offering fresh insights into its operations and strategy. The filing attaches Exhibit 99.1 but discloses no specific financial figures or material events beyond the update itself. Investors get a snapshot of the biotech firm's direction. Details remain in the presentation.
10-Q
Q2 FY2025 results
eXoZymes posted a Q2 net loss of $2.4M, up 73.5% y/y, with operating costs climbing 91.8% to $2.5M on higher compensation and R&D amid reduced grants. For the half-year, the net loss widened to $4.2M from $2.4M y/y, driven by 71.3% higher G&A and 167.6% increased net R&D to $1.4M, while stock-based comp added $0.9M. Cash burned $2.7M in operations, leaving $7.0M on hand with no debt, yet the pre-revenue firm faces going concern doubts. No non-GAAP metrics disclosed in the 10-Q. Tariffs could hike costs and crimp grants.
8-K
Shareholders approve key proposals
eXoZymes Inc. shareholders convened their 2025 Annual Meeting on July 25, electing six directors—Christopher A. Marlett, Anthony DiGiandomenico, James U. Bowie, James J. Lalonde, Lon E. Bell, and Edgardo Rayo—with overwhelming support exceeding 4.2 million votes each. They approved the 2025 Performance Equity Plan by a wide margin and ratified RBSM LLP as auditors for the fiscal year ending December 31, 2025. Advisory votes favored triennial say-on-pay frequency. Strong turnout signals board stability.
8-K
Updated investor presentation released
eXoZymes Inc. released an updated investor presentation on July 7, 2025, under Item 8.01, providing fresh insights into its operations and strategy. This move signals ongoing engagement with investors amid its emerging growth status on Nasdaq. Details remain in the exhibit. No financial impacts disclosed.
8-K
eXoZymes joins $9M NSF project
eXoZymes Inc. joined the NSF-funded Meta-PURE initiative on June 26, 2025, securing a $3 million share of the $9.2 million award to develop a cell-free ATP-generating module and a santalene production module. Led by Georgia Tech, the three-year project starting July 1 boosts cell-free biomanufacturing scalability for nutraceuticals, chemicals, and pharmaceuticals. This partnership decouples power from production for faster reactions and higher yields. Forward-looking statements highlight potential risks in execution.
AXIM
Axim Biotechnologies, Inc.
0.01+0.00
CDXS
Codexis, Inc.
2.42-0.17
CPMV
Mosaic ImmunoEngineering Inc.
0.84+0.33
ENTO
Entero Therapeutics Inc.
4.46+0.51
ENZN
Enzon Pharmaceuticals, Inc.
0.06+0.00
IMA
ImageneBio, Inc.
8.79+0.09
LENZ
LENZ Therapeutics, Inc.
30.64-0.17
QTZM
Quantumzyme Corp.
1.29+0.06
VIVS
VivoSim Labs, Inc.
2.30+0.02
XCUR
Exicure, Inc.
4.46-0.09